Celltrion headquarters in Incheon Celltrion posted a weaker-than-expected operating profit of 183 billion won ($137.7 million) in the second quarter, despite growing sales of biosimilar products. The profit was down 10.1 percent on year, missing the market consensus of 198.4 billion won. Revenues fell 12.1 percent to 524 billion won, also falling short of the 607.5 billion won market expectation. Net profit stood at 151 billion won, missing the analyst estimate of 158 billion won. "Profitability fell due to the low sales of chemical-based drugs, but sales of biosimilars rose 10.

https://n.news.naver.com/mnews/article/640/0000042071?sid=101

#naver